The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2018 | Pulmonary infiltration of CLL: implications for treatment
In chronic lymphocytic leukemia (CLL), treatment is often delayed because patients develop infections. Florence Cymbalista, PhD, from the Hôpital Avicenne, Bobigny, France, presented results at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, from a study investigating these patients. She found, using bronchoalveolar lavage and fibroscopy, that the patients who developed infections displayed pulmonary localizations of CLL. She discusses the potential for detecting which patients are at risk from infection, and the importance of treating those patients early to prevent further pulmonary infiltration of CLL.
